Akèy › Karsinom epatoseililè fibrolamèlè
Etid klinik pou Karsinom epatoseililè fibrolamèlè ap rekrite nan Etazini
5 etid pou Karsinom epatoseililè fibrolamèlè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07430202Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou May 19, 2026 · NCT05468359Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Ap rekriteFaz 2
Laj 0 a 30 · Tout sèks · Mizajou Feb 24, 2026 · NCT04134559DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Feb 12, 2026 · NCT06027086DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Dec 3, 2025 · NCT04248569Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.